Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,927 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study.
Ishida T, Ito S, Tanaka J, Uchiyama M, Kawano Y, Moreau P, Martin T, Risse ML, Tada K, Suzuki K, Ishizawa K. Ishida T, et al. Jpn J Clin Oncol. 2022 Dec 5;52(12):1446-1449. doi: 10.1093/jjco/hyac137. Jpn J Clin Oncol. 2022. PMID: 36073950 Free PMC article. Clinical Trial. No abstract available.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Dimopoulos MA, et al. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26671818 Free article. Clinical Trial.
A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.
Watanabe T, Tobinai K, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Kashihara T, Iida S. Watanabe T, et al. Among authors: ishida t. Br J Haematol. 2016 Mar;172(5):745-56. doi: 10.1111/bjh.13900. Epub 2016 Jan 5. Br J Haematol. 2016. PMID: 26732066 Free PMC article. Clinical Trial.
[IgE-κ type multiple myeloma achieving complete response with novel agents].
Takei T, Ishida T, Ikeda M, Shingaki S, Miyazaki K, Yoshiki Y, Abe Y, Okazuka K, Iki S, Tsukada N, Suzuki K. Takei T, et al. Among authors: ishida t. Rinsho Ketsueki. 2017;58(11):2232-2237. doi: 10.11406/rinketsu.58.2232. Rinsho Ketsueki. 2017. PMID: 29212974 Review. Japanese.
4,927 results